Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Abbott Laboratories : Today's Research Reports on Stocks to Watch: Abbott Laboratories and Pfizer Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/21/2017 | 02:46pm CEST
NEW YORK, NY / ACCESSWIRE / July 21, 2017 / Abbott Laboratories saw its shares climb higher yesterday after announcing Q2 results that narrowly beat Wall Street's expectations. Shares of Pfizer saw a loss after it was revealed that the pharmaceutical giant is facing two patent expirations, for Viagra, and Lyrica, two drugs that accounted for 4.2 billion or more in domestic sales in 2016.

RDI Initiates Coverage on:

Abbott Laboratories
https://ub.rdinvesting.com/news/?ticker=ABT

Pfizer Inc.
https://ub.rdinvesting.com/news/?ticker=PFE

Abbott Laboratories shares closed up 2.87% yesterday and hit a new high of $51.13. Volume for the stock was also nearly double compared to usual. So why was the stock near its all-time new high? The American worldwide health care company reported its second quarter financial results and both profits and revenue narrowly topped what analysts had been expecting. For the second quarter ended June 30th, the company reported income of 62 cents a share. Wall Street had been looking for 60 cents a share. The medical giant also increased its forecast for 2017 profits from $2.43 to $2.53. According to RBC analyst Glenn Novarro, analysts had called for $2.47 earnings per share. RBC has an "outperform" rating on the stock.

Access RDI's Abbott Laboratories Research Report at:
https://ub.rdinvesting.com/news/?ticker=ABT

Pfizer Inc. shares closed down a modest 0.24% on Thursday with nearly 17 million shares traded. It was a bad news day for the company. According to analysts at Credit Suisse, Pfizer is looking at not one, but two patent expirations for its male impotency treatment drug Viagra and its drug Lyrica, which treats nerve damage. The patents were described as "meaningful." Analyst Vamil Divan stated, "We have been long-time supporters of the PFE story and see opportunities for upside over the long-term, but see more limited drivers of upside over the next 6-12 months." Divan expects Pfizer to lose the U.S. patent exclusively for Viagra in December of this year and to lose the patent for Lyrica next year. He reduced his earnings per share targets for next year to $2.71 from $2.78. He also cut his price target on the stock from $38 to $36.

Access RDI's Pfizer Inc. Research Report at:
https://ub.rdinvesting.com/news/?ticker=PFE

Our Actionable Research on Abbott Laboratories (NYSE: ABT) and Pfizer Inc. (NYSE: PFE) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer or a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com


© Accesswire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBOTT LABORATORIES
07/21 ABBOTT LABORATORIES : Today's Research Reports on Stocks to Watch: Abbott Labora..
07/21 ABBOTT LABORATORIES : $30,000 Federal Contract Awarded to Abbott Laboratories
07/20 PPG and C.H. Robinson slip while Abbott and Sears advance
07/20 Abbott profit forecast gets a lift from St. Jude integration
07/20 ABBOTT LABORATORIES (NYSE : ABT) reported earnings of $0.62 per share beating Wa..
07/20 ABBOTT LABORATORIES : revenue grows 4.4 percent, but pacemaker sales drop
07/20 ABBOTT LABORATORIES (NYSE : ABT) Files An 8-K Results of Operations and Financia..
07/20 ABBOTT LABORATORIES : tops Street 2Q forecasts
07/20 ABBOTT LABORATORIES : Results of Operations and Financial Condition, Financial S..
07/20 ABBOTT : Reports Second-Quarter 2017 Results
More news
News from SeekingAlpha
07/24 ABIOMED : This Debt-Free Medical Device Stock Is A Strong Buy In 2017
07/24 A REVIEW OF THE DIVIDEND HOUSE PORTF : Time For A House Inspection
07/21 WALL STREET BREAKFAST : Confidence In Bitcoin Is Back
07/20 Quidel To Acquire Triage Assets From Alere Divestiture
07/20 Abbott's (ABT) CEO Miles White on Q2 2017 Results - Earnings Call Transcript
Financials ($)
Sales 2017 26 469 M
EBIT 2017 5 747 M
Net income 2017 2 348 M
Debt 2017 15 007 M
Yield 2017 2,11%
P/E ratio 2017 42,96
P/E ratio 2018 27,93
EV / Sales 2017 3,90x
EV / Sales 2018 3,62x
Capitalization 88 204 M
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 55,1 $
Spread / Average Target 8,3%
EPS Revisions
Managers
NameTitle
Miles D. White Chairman & Chief Executive Officer
Brian B. Yoor Chief Financial Officer & Executive VP-Finance
Roxanne Schuh Austin Independent Director
Jim Farrell Independent Director
Samuel C. Scott Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES32.34%88 204
JOHNSON & JOHNSON14.47%355 263
NOVARTIS7.35%220 651
ROCHE HOLDING LTD.4.30%220 599
PFIZER1.91%197 115
MERCK AND COMPANY5.93%170 565